Halozyme Therapeutics | HALO - Current Liabilities


Halozyme Therapeutics reported $363.21M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Agios Pharmaceuticals USD 58.84M 23.36M Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Amarin USD 179.64M 14.82M Mar/2026
Amgen USD 24.96B 534M Mar/2026
Baxter International USD 3.69B 723M Mar/2026
Cara Therapeutics USD 11.04M 2K Dec/2025
Cytokinetics USD 199.18M 3.27M Mar/2026
DBV Technologies USD 58.02M 8.54M Dec/2025
Eli Lilly USD 36.63B 1.41B Mar/2026
Esperion Therapeutics USD 300.36M 451K Mar/2026
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Intrexon USD 23.02M 38K Jun/2024
Ionis Pharmaceuticals USD 717M 66M Mar/2026
MannKind USD 134.56M 36.47M Mar/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Pfizer USD 34.35B 2.64B Mar/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
United Therapeutics USD 599.1M 38.5M Mar/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025